Valentina Boni, MD, PhD, on Breast Cancer Advances from 2022 ASCO

Video

Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.

CancerNetwork® spoke with Valentina Boni, MD, PhD, of the Early Drug Development Unit at the Universitary Hospital Universitario Quirónsalud Madrid as well as director and principal investigator at NEXT Oncology Madrid in Spain, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about top trials in breast cancer.

Transcript:

2022 ASCO was a very interesting meeting, as always. The most important thing is that we had an opportunity to meet with other collaborative persons after more than 2 years. There are several other trials that are very interesting. The [phase 3] TROPiCS-02 [NCT03901339] with sacituzumab govitecan [Trodelvy] in patients with breast cancer that is hormone receptor–positive is a very important new trial, especially because it is a new antibody-drug conjugate that was previously approved in triple-negative breast cancer. It is going to be another standard of [care] therapy in hormone receptor–positive breast cancer.1,2

In the plenary session, the results of [phase 3] DESTINY-Breast04 trial [NCT03734029] were presented.3 The activity of trastuzumab deruxtecan [Enhertu] in patients with hormone receptor–positive/HER2-low breast cancer. That is going to be a new standard of care for these patients. We have a lot of new and interesting data, and some of them are going to change the clinical practice in metastatic breast cancer.

References

  1. Rugo HS, Bardia A, Marme F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40(suppl 17):LBA1001-LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
  2. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. News Release. FDA. April 7, 2021. Accessed July 8, 2022. https://bit.ly/3yN1Vzz
  3. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content